source
- Sanofi asks FDA to withdraw teplizumab from fast-track review after internal disagreementSanofi has formally requested that the U.S. Food and Drug Administration remove its type 1 diabetes therapy, teplizumab, from the agency's new speedy review program. The request follows a disagree…
- Experts preview promising triple-negative breast cancer studies for ASCO 2026At the 2026 ASCO Annual Meeting, leading breast cancer specialists highlighted the triple-negative breast cancer (TNBC) abstracts they consider most likely to influence clinical practice. The disc…